SCLX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -229.58% compared to Scilex Holding's net margin of --. Scilex Holding's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 1933.43%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Scilex Holding has higher upside potential than Perspective Therapeutics, analysts believe Scilex Holding is more attractive than Perspective Therapeutics.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Scilex Holding's net income of -$37.6M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Scilex Holding's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 1.01x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -229.58% compared to Scilex Holding's net margin of 10.05%. Scilex Holding's return on equity of -- beat Electromed's return on equity of 15.62%.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 1933.43%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 19.01%. Given that Scilex Holding has higher upside potential than Electromed, analysts believe Scilex Holding is more attractive than Electromed.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Electromed quarterly revenues of $14.7M. Scilex Holding's net income of -$37.6M is lower than Electromed's net income of $1.5M. Notably, Scilex Holding's price-to-earnings ratio is -- while Electromed's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 1.01x versus 4.33x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -229.58% compared to Scilex Holding's net margin of 1.94%. Scilex Holding's return on equity of -- beat Masimo's return on equity of 5.75%.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 1933.43%. On the other hand Masimo has an analysts' consensus of $172.77 which suggests that it could grow by 1.9%. Given that Scilex Holding has higher upside potential than Masimo, analysts believe Scilex Holding is more attractive than Masimo.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Masimo has a beta of 1.010, suggesting its more volatile than the S&P 500 by 1.04%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are smaller than Masimo quarterly revenues of $504.6M. Scilex Holding's net income of -$37.6M is lower than Masimo's net income of $9.8M. Notably, Scilex Holding's price-to-earnings ratio is -- while Masimo's PE ratio is 116.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 1.01x versus 4.51x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals has a net margin of -229.58% compared to Scilex Holding's net margin of --. Scilex Holding's return on equity of -- beat Oramed Pharmaceuticals's return on equity of --.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 1933.43%. On the other hand Oramed Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 36.56%. Given that Scilex Holding has higher upside potential than Oramed Pharmaceuticals, analysts believe Scilex Holding is more attractive than Oramed Pharmaceuticals.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oramed Pharmaceuticals has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.699%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Oramed Pharmaceuticals pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Oramed Pharmaceuticals quarterly revenues of --. Scilex Holding's net income of -$37.6M is lower than Oramed Pharmaceuticals's net income of -$19.6M. Notably, Scilex Holding's price-to-earnings ratio is -- while Oramed Pharmaceuticals's PE ratio is 21.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 1.01x versus 36.45x for Oramed Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.